ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.73 Billion KRW | 66.85% |
| 2022 | -29.37 Billion KRW | -93.35% |
| 2021 | -15.19 Billion KRW | -26017.17% |
| 2020 | -58.16 Million KRW | 97.42% |
| 2019 | -2.25 Billion KRW | 70.6% |
| 2018 | -7.65 Billion KRW | -24.08% |
| 2017 | -6.17 Billion KRW | -14.09% |
| 2016 | -5.41 Billion KRW | -4462.41% |
| 2015 | 124.04 Million KRW | -82.87% |
| 2014 | 724.2 Million KRW | -52.06% |
| 2013 | 1.51 Billion KRW | -9.0% |
| 2012 | 1.66 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.72 Billion KRW | -138.98% |
| 2024 Q1 | 17.25 Billion KRW | 313.79% |
| 2023 FY | -9.73 Billion KRW | 66.85% |
| 2023 Q3 | -10.58 Billion KRW | -154.55% |
| 2023 Q4 | -8.07 Billion KRW | 23.77% |
| 2023 Q2 | 19.41 Billion KRW | 285.13% |
| 2023 Q1 | -10.48 Billion KRW | -280.48% |
| 2022 FY | -29.37 Billion KRW | -93.35% |
| 2022 Q4 | -2.75 Billion KRW | 74.25% |
| 2022 Q3 | -10.7 Billion KRW | -14.94% |
| 2022 Q2 | -9.31 Billion KRW | -40.93% |
| 2022 Q1 | -6.6 Billion KRW | -176.51% |
| 2021 Q3 | -10.15 Billion KRW | 3.5% |
| 2021 Q4 | 8.63 Billion KRW | 185.07% |
| 2021 Q1 | -1.46 Billion KRW | 82.0% |
| 2021 FY | -15.19 Billion KRW | -26017.17% |
| 2021 Q2 | -10.51 Billion KRW | -617.26% |
| 2020 Q2 | 2.49 Billion KRW | 89.66% |
| 2020 Q4 | -8.14 Billion KRW | -290.68% |
| 2020 Q3 | 4.27 Billion KRW | 70.99% |
| 2020 FY | -58.16 Million KRW | 97.42% |
| 2020 Q1 | 1.31 Billion KRW | -80.05% |
| 2019 Q3 | -3.05 Billion KRW | -36.65% |
| 2019 Q1 | -3.56 Billion KRW | -180.45% |
| 2019 FY | -2.25 Billion KRW | 70.6% |
| 2019 Q4 | 6.6 Billion KRW | 316.21% |
| 2019 Q2 | -2.23 Billion KRW | 37.32% |
| 2018 FY | -7.65 Billion KRW | -24.08% |
| 2018 Q4 | -1.27 Billion KRW | 59.21% |
| 2018 Q3 | -3.11 Billion KRW | -58.11% |
| 2018 Q2 | -1.97 Billion KRW | -51.87% |
| 2018 Q1 | -1.29 Billion KRW | 62.45% |
| 2017 Q2 | -2.06 Billion KRW | -325.76% |
| 2017 FY | -6.17 Billion KRW | -14.09% |
| 2017 Q4 | -3.45 Billion KRW | -120.86% |
| 2017 Q1 | 914.27 Million KRW | 156.57% |
| 2017 Q3 | -1.56 Billion KRW | 24.14% |
| 2016 Q2 | -1.38 Billion KRW | -33.09% |
| 2016 Q4 | -1.61 Billion KRW | -18.47% |
| 2016 FY | -5.41 Billion KRW | -4462.41% |
| 2016 Q1 | -1.04 Billion KRW | -283.97% |
| 2016 Q3 | -1.36 Billion KRW | 1.71% |
| 2015 Q2 | -650.02 Million KRW | -229.17% |
| 2015 Q1 | 503.24 Million KRW | 263.0% |
| 2015 FY | 124.04 Million KRW | -82.87% |
| 2015 Q4 | 566.83 Million KRW | 291.49% |
| 2015 Q3 | -296.01 Million KRW | 54.46% |
| 2014 Q4 | -308.73 Million KRW | -301.87% |
| 2014 FY | 724.2 Million KRW | -52.06% |
| 2014 Q1 | 353.95 Million KRW | 88.67% |
| 2014 Q2 | 526.04 Million KRW | 48.62% |
| 2014 Q3 | 152.94 Million KRW | -70.93% |
| 2013 FY | 1.51 Billion KRW | -9.0% |
| 2013 Q1 | 567.76 Million KRW | 0.0% |
| 2013 Q2 | 567.76 Million KRW | 0.0% |
| 2013 Q4 | 187.6 Million KRW | 0.0% |
| 2013 Q3 | 187.6 Million KRW | -66.96% |
| 2012 FY | 1.66 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 92.212% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -196.407% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 1034.202% |
| Bioneer Corporation | 791.75 Million KRW | 1329.783% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -91.903% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 61.255% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 68.502% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 72.374% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | -3.307% |
| Medy-Tox Inc. | 17.32 Billion KRW | 156.21% |
| Peptron, Inc. | -15.6 Billion KRW | 37.596% |
| Amicogen, Inc. | 2.05 Billion KRW | 573.549% |
| Genexine, Inc. | -41.24 Billion KRW | 76.39% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -11.914% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 87.953% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 109.658% |
| SillaJen, Inc. | -21.34 Billion KRW | 54.385% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 469.71% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 46.458% |
| Genomictree Inc. | -17.3 Billion KRW | 43.729% |
| MedPacto, Inc. | -28.75 Billion KRW | 66.135% |
| D&D Pharmatech | -13.48 Billion KRW | 27.802% |
| EASY BIO,Inc. | 20.63 Billion KRW | 147.195% |
| GI Innovation, Inc. | -55.6 Billion KRW | 82.489% |